Extended Hemophilia Treatment Safe and Effective in Children

Article

Combination of recombinant factor VIII with a fusion protein allows for less frequent treatment.

Combination of recombinant factor VIII with a fusion protein allows for less frequent treatment.

A long lasting novel anti-hemophilia therapy was found to be safe and effective for use in children in a recent study.

During treatment for hemophilia A, children receive 3 to 4 infusions per week to prevent bleeding episodes, chronic pain, and joint damage. The frequent injections can affect quality of life due to discomfort from the infusions.

As a result of the diminished quality of life, children are commonly under-dosed, which increases the risk for bleeding episodes and death. The study, published in the Journal of Thrombosis and Haemostasis, evaluated the extended half-life factor VIII, which allows patients to receive 1 or 2 infusions per week without an increased bleeding risk.

Hemophilia patients are typically treated with replacement therapy and receive infusions of the clotting factor that is deficient in their blood. These infusions keep the factor at a protective blood level that allows for clotting when an injury occurs.

Current treatment with factor VIII persists in the blood for a relatively short duration, which subsequently requires infusions every other day.

The extended therapy combines recombinant factor VIII with a fusion protein to allow the molecule to remain in circulation longer, which leads to less frequent treatment. The researchers found that twice-weekly infusions of the novel therapy were well tolerated and caused low incidence of bleeding events in children with severe hemophilia A.

It was also noted that no patients developed inhibitor antibodies against the factor.

"Through clinical trials, we are able to offer our patients the very latest treatments, often before they are available anywhere else,” said study lead Guy Young, MD, in a press release. “In this trial, we demonstrated the safety and efficacy of a medication that will allow children with severe hemophilia A to be treated with a safe and effective medicine but with a reduced burden of the treatment."

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.